Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

Adoptive cell transfer (ACT) of purified naive, stem cell memory, and central memory T cell subsets results in superior persistence and antitumor immunity compared with ACT of populations containing more-differentiated effector memory and effector T cells. Despite a clear advantage of the less-differentiated populations, the majority of ACT trials utilize unfractionated T cell subsets. Here, we have challenged the notion that the mere presence of less-differentiated T cells in starting populations used to generate therapeutic T cells is sufficient to convey their desirable attributes. Using both mouse and human cells, we identified a T cell-T cell interaction whereby antigen-experienced subsets directly promote the phenotypic, functional, and metabolic differentiation of naive T cells. This process led to the loss of less-differentiated T cell subsets and resulted in impaired cellular persistence and tumor regression in mouse models following ACT. The T memory-induced conversion of naive T cells was mediated by a nonapoptotic Fas signal, resulting in Akt-driven cellular differentiation. Thus, induction of Fas signaling enhanced T cell differentiation and impaired antitumor immunity, while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populations. These findings reveal that T cell subsets can synchronize their differentiation state in a process similar to quorum sensing in unicellular organisms and suggest that disruption of this quorum-like behavior among T cells has potential to enhance T cell-based immunotherapies.

[1]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[2]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Mark S. Sundrud,et al.  Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. , 2015, Cancer research.

[4]  T. Speed,et al.  Distinct epigenetic signatures delineate transcriptional programs during virus-specific CD8(+) T cell differentiation. , 2014, Immunity.

[5]  Christian Stemberger,et al.  Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. , 2014, Immunity.

[6]  C. Creighton,et al.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. , 2014, Blood.

[7]  G. Lythe,et al.  A mathematical perspective on CD4(+) T cell quorum-sensing. , 2014, Journal of theoretical biology.

[8]  B. Levine,et al.  Adoptive immunotherapy for cancer or viruses. , 2014, Annual review of immunology.

[9]  H. Heslop,et al.  Antiviral T‐cell therapy , 2014, Immunological reviews.

[10]  S. Riddell,et al.  Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cells , 2014, Immunological reviews.

[11]  S. Gottschalk,et al.  Design and development of therapies using chimeric antigen receptor‐expressing T cells , 2014, Immunological reviews.

[12]  T. Speed,et al.  Distinct Epigenetic Signatures Delineate Transcriptional Programs during Virus-Specific CD8 T Cell Differentiation , 2014 .

[13]  A. Liston,et al.  IL-2 coordinates IL-2–producing and regulatory T cell interplay , 2013, The Journal of experimental medicine.

[14]  P. Muranski,et al.  Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. , 2013, The Journal of clinical investigation.

[15]  A. Scheffold,et al.  Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients , 2013, Cancer Immunology, Immunotherapy.

[16]  P. Darcy,et al.  Gene-engineered T cells for cancer therapy , 2013, Nature Reviews Cancer.

[17]  Arup K Chakraborty,et al.  Quorum sensing allows T cells to discriminate between self and nonself , 2013, Proceedings of the National Academy of Sciences.

[18]  J. Rathmell,et al.  Metabolic regulation of T lymphocytes. , 2013, Annual review of immunology.

[19]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[20]  Omar Khan,et al.  Secondary T cell–T cell synaptic interactions drive the differentiation of protective CD8+ T cells , 2013, Nature Immunology.

[21]  S. Bicciato,et al.  IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. , 2013, Blood.

[22]  R. Brentjens with Chemotherapy-Refractory Acute Lymphoblastic Leukemia CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults , 2013 .

[23]  C. Klebanoff,et al.  Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy? , 2012, Journal of immunotherapy.

[24]  Bonnie L Bassler,et al.  Bacterial quorum sensing: its role in virulence and possibilities for its control. , 2012, Cold Spring Harbor perspectives in medicine.

[25]  C. Klebanoff,et al.  Paths to stemness: building the ultimate antitumour T cell , 2012, Nature Reviews Cancer.

[26]  H. Heslop,et al.  T-cell therapy in the treatment of post-transplant lymphoproliferative disease , 2012, Nature Reviews Clinical Oncology.

[27]  D. Fearon,et al.  Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell , 2012, Proceedings of the National Academy of Sciences.

[28]  U. V. von Andrian,et al.  Chemokine Guidance of Central Memory T Cells Is Critical for Antiviral Recall Responses in Lymph Nodes , 2012, Cell.

[29]  Christian Stemberger,et al.  Novel Serial Positive Enrichment Technology Enables Clinical Multiparameter Cell Sorting , 2012, PloS one.

[30]  Qingsheng Li,et al.  Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation. , 2012, Immunity.

[31]  J. Harty,et al.  Population Dynamics of Naive and Memory CD8 T Cell Responses after Antigen Stimulations In Vivo , 2012, The Journal of Immunology.

[32]  C. Turtle,et al.  Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. , 2012, Blood.

[33]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[34]  M. D. Martin,et al.  The Impact of Pre-Existing Memory on Differentiation of Newly Recruited Naive CD8 T Cells , 2011, The Journal of Immunology.

[35]  T. Schumacher,et al.  T-cell receptor gene therapy: critical parameters for clinical success. , 2011, The Journal of investigative dermatology.

[36]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[37]  F. Marincola,et al.  A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.

[38]  S. Rosenberg,et al.  Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice , 2011, Clinical Cancer Research.

[39]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[40]  S. Price,et al.  Specific elimination of effector memory CD4+ T cells due to enhanced Fas signaling complex formation and association with lipid raft microdomains , 2011, Cell Death and Differentiation.

[41]  S. John,et al.  Subcellular Localization of Hexokinases I and II Directs the Metabolic Fate of Glucose , 2011, PloS one.

[42]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  David K. Finlay,et al.  Protein Kinase B Controls Transcriptional Programs that Direct Cytotoxic T Cell Fate but Is Dispensable for T Cell Metabolism , 2011, Immunity.

[44]  W. Burns,et al.  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. , 2011, Blood.

[45]  S. Riddell,et al.  Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. , 2011, Blood.

[46]  M. Kalos,et al.  Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[47]  G. Dotti,et al.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. , 2010, Blood.

[48]  M. Sadelain T-cell engineering for cancer immunotherapy. , 2009, Cancer journal.

[49]  Yun Ji,et al.  Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity , 2009, Proceedings of the National Academy of Sciences.

[50]  Bruce R. Blazar,et al.  Engineering lymphocyte subsets: tools, trials and tribulations , 2009, Nature Reviews Immunology.

[51]  E. Meffre,et al.  Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. , 2009, Immunity.

[52]  G. V. van Dooren,et al.  Dynamics of T cell, antigen-presenting cell, and pathogen interactions during recall responses in the lymph node. , 2009, Immunity.

[53]  R. Sprengel,et al.  The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. , 2009, Cell stem cell.

[54]  P. Muranski,et al.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.

[55]  M. Croft The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.

[56]  Daniel R. Beisner,et al.  Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor , 2009, Nature Immunology.

[57]  V. Lazar,et al.  FOXO1 Regulates L-Selectin and a Network of Human T Cell Homing Molecules Downstream of Phosphatidylinositol 3-Kinase1 , 2008, The Journal of Immunology.

[58]  Junsang Doh,et al.  A synaptic basis for paracrine interleukin-2 signaling during homotypic T cell interaction. , 2008, Immunity.

[59]  I. Sancho-Martinez,et al.  Yes and PI3K bind CD95 to signal invasion of glioblastoma. , 2008, Cancer cell.

[60]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[61]  Nikhil S. Joshi,et al.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. , 2007, Immunity.

[62]  David K. Finlay,et al.  Notch-induced T cell development requires phosphoinositide-dependent kinase 1 , 2007, The EMBO journal.

[63]  Ronald N Germain,et al.  L-selectin-negative CCR7− effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells , 2007, Nature Immunology.

[64]  M. Peter,et al.  The CD95 Receptor: Apoptosis Revisited , 2007, Cell.

[65]  M. Peter,et al.  Palmitoylation of CD95 facilitates formation of SDS‐stable receptor aggregates that initiate apoptosis signaling , 2007, The EMBO journal.

[66]  D. Marguet,et al.  Palmitoylation is required for efficient Fas cell death signaling , 2007, The EMBO journal.

[67]  P. Fink,et al.  The Cytoplasmic Domain of Fas Ligand Costimulates TCR Signals1 , 2006, The Journal of Immunology.

[68]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[69]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[70]  P. Hammerman,et al.  Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival , 2003, Molecular and Cellular Biology.

[71]  P. Corthésy,et al.  Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. , 2003, Blood.

[72]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[73]  C. Thompson,et al.  The CD28 signaling pathway regulates glucose metabolism. , 2002, Immunity.

[74]  Philippa Marrack,et al.  T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells , 2000, The Journal of experimental medicine.

[75]  J. Desbarats,et al.  Fas engagement accelerates liver regeneration after partial hepatectomy , 2000, Nature Medicine.

[76]  S. Jameson,et al.  Expression of the transcription factor lung Krüppel-like factor is regulated by cytokines and correlates with survival of memory T cells in vitro and in vivo. , 1999, Journal of immunology.

[77]  D. Dimitrov,et al.  Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. , 1997, Blood.

[78]  Kristin A. Hogquist,et al.  T cell receptor antagonist peptides induce positive selection , 1994, Cell.

[79]  F. Ramsdell,et al.  Fas transduces activation signals in normal human T lymphocytes , 1993, The Journal of experimental medicine.

[80]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.